About:
BioHybrid Solutions is developing next-generation protein therapeutics called NanoArmoredTM protein-polymer conjugates. A major problem facing the pharmaceutical industry is how longer-lived, more effective medicines can be generated. BioHybrid is using their systematic in silico and in vitro process to improve the pharmacokinetics and increase the half-life of NanoArmoredTM biologic therapeutics while maintaining activity. In the past six years, BioHybrid has created a number of custom NanoArmored proteins for a variety of therapeutics to meet the clinical needs of both civilian and military populations. BioHybrids most advanced drug, BHS-001 is being developed as nerve agent prophylactics.